Sun Pharma to commercially launch Philogen’s skin cancer drug in Europe, Australia & New Zealand

INDIA – Sun Pharma is set to begin the commercialization of novel skin cancer drug, Nidlegy, across the territories of Europe, Australia, and New Zealand following a licensing agreement with Philogen.

Nidlegy, currently in Phase III clinical trials, is a new anti-cancer biopharmaceutical that is being developed by Philogen for the treatment of melanoma and non-melanoma skin cancers.

Under the terms of the latest exclusive agreement, Sun Pharma will be responsible for the commercialization activities of this new cancer product in the specified regions.

Philogen will complete pivotal clinical trials for the specialty product in Europe under the terms of this agreement.

The Swiss-Italian integrated biotechnology company will continue pursuing Marketing Authorization with the regulatory authorities and manufacturing commercial supplies.

Moreover, the biotechnology company will retain intellectual property rights (IP) for Nidlegy outside Europe, Australia, and New Zealand.

Philogen also has rights over the commercialization of Nidlegy for indications other than skin cancers per the provisions of the new licensing pact.

Sun Pharma and Philogen will share post-commercialization economics in about a 50:50 ratio, the companies claimed.

This strategic alliance comes as Sun Pharma has exclusive rights to the oncology product Odomzo (sonidegib) for global markets following an exclusive agreement with Swiss pharma giant Novartis.

Sun Pharma has expanded its existing dermatology and oncology infrastructure with the commercial launch of Nidlegy in Europe, Australia, and New Zealand.

It complements and enhances the company’s existing Dermatology franchise, which provides patient solutions across a broad spectrum of skin conditions in various disease stages.

Expanding its presence in the onco-dermatology space, Sun Pharma is expected to accelerate the market entry of Nidlegy as a new immunotherapy treatment for skin cancers.

This partnership will deepen Sun Pharma’s presence in the specialty product market in line with its goal to bring innovative products to patients.

For this reason, the Mumbai-based pharma major will harness its global reach and commercial capabilities to enhance access to Nidlegy for patients with skin cancers around the world.

The milestone builds on India’s largest drugmaker mission to establish itself as a preferred development and commercial partner in Dermatology and Ophthalmology therapies worldwide.

In another development, Sun Pharma wrapped up the acquisition of Concert with the desire to bring deuruxolitinib, a potential best-in-class treatment for alopecia areata, to market globally.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.